Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer

Geng,Biao; Liang,Man-Man; Ye,Xiao-Bing; Zhao,Wen-Ying

doi:10.3892/mco.2014.419

Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer

Authors:
- Biao Geng
- Man-Man Liang
- Xiao-Bing Ye
- Wen-Ying Zhao
View Affiliations

Affiliations: Department of Medical Oncology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China, Department of Internal Medicine, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China
Published online on: September 18, 2014 https://doi.org/10.3892/mco.2014.419
Pages: 232-236

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of this study was to investigate the association of serum cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) levels with clinicopathological parameters in patients diagnosed with metastatic breast cancer (MBC). We retrospectively evaluated the medical records of 284 patients diagnosed with MBC between January, 2007 and December, 2012 who fulfilled the specified criteria and the association between the levels of the two tumor marker and clinicopathological parameters was analyzed. Of the 284 patients, elevated CA 15-3 and CEA levels at initial diagnosis of recurrence were identified in 163 (57.4%) and 97 (34.2%) patients, respectively. Elevated CA 15-3 and CEA levels were significantly associated with breast cancer molecular subtypes (P<0.001 and P=0.032, respectively). Cases with luminal subtypes exhibited a higher percentage of elevated CA 15-3 and CEA levels compared to non-luminal subtypes. Elevated CA 15-3 level was correlated with bone metastasis (P=0.017). However, elevation of CEA was observed regardless of the site of metastasis. Elevation of CA 15-3 was significantly more common in MBC with multiple metastatic sites compared to MBC with a single metastasis (P=0.001). However, the incidence of elevated CEA levels did not differ between patients with a single and those with multiple metastatic sites. In conclusion, elevated CA 15-3 and CEA levels at initial diagnosis of recurrence were found to be associated with breast cancer molecular subtypes, whereas an elevated CA 15-3 level was significantly correlated with bone metastasis and an elevated CEA level was observed regardless of metastatic site. The proportion of MBC cases with elevated CA 15-3 levels differed according to the number of metastatic sites.

View Figures

View References

1	Li J, Zhang BN, Fan JH, et al: A nation-wide multicenter 10-year (1999–2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer. 11:3642011.
2	Early Breast Cancer Trialists' Collaborative Group (EBCTCG), . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 365:1687–1717. 2005.PubMed/NCBI
3	Sayer HG, Kath R, Kliche KO and Höffken K: Premenopausal breast cancer: chemotherapy and endocrine therapy. Drugs. 62:2025–2038. 2002. View Article : Google Scholar : PubMed/NCBI
4	de Bono JS, Tolcher AW and Rowinsky EK: The future of cytotoxic therapy: selective cytotoxicity based on biology is the key. Breast Cancer Res. 5:154–159. 2003.PubMed/NCBI
5	Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI
6	Park BW, Oh JW, Kim JH, et al: Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol. 19:675–681. 2008. View Article : Google Scholar : PubMed/NCBI
7	Lee JS, Park S, Park JM, Cho JH, Kim SI and Park BW: Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol. 24:1225–1231. 2013. View Article : Google Scholar : PubMed/NCBI
8	Nicolini A, Tartarelli G, Carpi A, et al: Intensive post-operative follow-up of breast cancer patients with tumor markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 6:2692006. View Article : Google Scholar
9	Pedersen AC, Sørensen PD, Jacobsen EH, Madsen JS and Brandslund I: Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Clin Chem Lab Med. 51:1511–1519. 2013. View Article : Google Scholar : PubMed/NCBI
10	Yonemori K, Katsumata N, Noda A, et al: Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer. J Cancer Res Clin Oncol. 134:1199–1206. 2008. View Article : Google Scholar : PubMed/NCBI
11	Hashimoto K, Yonemori K, Katsumata N, et al: Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy. Ann Oncol. 21:2195–2200. 2010. View Article : Google Scholar
12	Molina R, Barak V, van Dalen A, et al: Tumor markers in breast cancer - European Groupon Tumor Markers recommendations. Tumor Biol. 26:281–293. 2005. View Article : Google Scholar : PubMed/NCBI
13	Jäger W, Eibner K, Löffler B, Gleixner S and Krämer S: Serial CEA and CA 15-3 measurements during follow-up of breast cancer patients. Anticancer Res. 20:5179–5182. 2000.PubMed/NCBI
14	Molina R, Jo J, Filella X, et al: c-erbB-2 oncoprotein, CEA, and CA 15-3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat. 51:109–119. 1998. View Article : Google Scholar : PubMed/NCBI
15	Lauro S, Trasatti L, Bordin F, et al: Comparison of CEA, MCA, CA 15-3 and CA 27–29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res. 19:3511–3515. 1999.
16	Tampellini M, Berruti A, Gorzegno G, et al: Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse. Tumor Biol. 22:367–373. 2001. View Article : Google Scholar
17	Lim E, Vaillant F, Wu D, et al: Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 15:907–913. 2009. View Article : Google Scholar : PubMed/NCBI
18	Cancer Genome Atlas Network, . Comprehensive molecular portraits of human breast tumor. Nature. 490:61–70. 2012. View Article : Google Scholar
19	Lee JS, Park S, Park JM, Cho JH, Kim SI and Park BW: Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers. Breast Cancer Res Treat. 141:477–484. 2013. View Article : Google Scholar : PubMed/NCBI
20	Yerushalmi R, Tyldesley S, Kennecke H, et al: Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol. 23:338–345. 2012. View Article : Google Scholar : PubMed/NCBI
21	al-Jarallah MA, Behbehani AE, el-Nass SA, et al: Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol. 19:74–79. 1993.PubMed/NCBI
22	Bidard FC, Hajage D, Bachelot T, et al: Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res. 14:R292012.PubMed/NCBI